Coherus Oncology
CHRS
93 hedge funds and large institutions have $627M invested in Coherus Oncology in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 44 increasing their positions, 24 reducing their positions, and 21 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 24
13.09% more ownership
Funds ownership: 78.28% → 91.37% (+13%)
9% more capital invested
Capital invested by funds: $576M → $627M (+$50.5M)
12% less funds holding
Funds holding: 106 → 93 (-13)
26% less call options, than puts
Call options by funds: $1.43M | Put options by funds: $1.92M
57% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
+$86.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.98M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.08M |
| 5 |
JP Morgan Chase
New York
|
+$4.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$25.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.9M |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$3.84M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$3.24M |
| 5 |
CCI
Columbus Circle Investors
|
-$2.73M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Schroder Investment Management Group
London,
United Kingdom
| – | -$417K | -28,879 | Closed |
|
|
JG
102
Jefferies Group
New York
| – | -$376K | -26,218 | Closed |
|
|
PIM
103
Partner Investment Management
San Francisco,
California
| – | -$348K | -24,236 | Closed |
|
104
Renaissance Technologies
New York
| – | -$314K | -21,900 | Closed |
|
|
CL
105
Croft-Leominster
Baltimore,
Maryland
| – | -$287K | -20,000 | Closed |
|
106
Jane Street
New York
| – | -$277K | -19,279 | Closed |
|
107
Jennison Associates
New York
| – | -$261K | -18,200 | Closed |
|
|
BA
108
Boston Advisors
Boston,
Massachusetts
| – | -$244K | -16,995 | Closed |
|
|
CSS
109
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$185K | -12,900 | Closed |
|
110
Russell Investments Group
London,
United Kingdom
| – | -$84K | -5,888 | Closed |
|
|
PHK
111
Point72 Hong Kong
Hong Kong
| – | -$48K | -3,328 | Closed |
|
|
PCM
112
Prelude Capital Management
New York
| – | -$17K | -1,200 | Closed |
|
113
Creative Planning
Overland Park,
Kansas
| – | -$3K | -200 | Closed |
|
114
US Bancorp
Minneapolis,
Minnesota
| – | +$132 | +10 | New |
|
CHRS Hedge Fund Activity: Q3 2017 in Review
93 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2017, worth a combined $627M — up 8.8% from $576M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of CHRS and 9 opened new positions — a net loss of 12 holders — while 24 trimmed existing stakes and 44 added.
The largest buyer was Temasek Holdings, opening a new position worth an estimated $86.7M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $25.9M sold.
- 93 institutional investors held Coherus Oncology (CHRS) as of Q3 2017, down from 106 in Q2 2017.
- Funds reported $627M of Coherus Oncology stock for Q3 2017, up 8.8% quarter-over-quarter.
- 9 funds opened new Coherus Oncology positions in Q3 2017 and 21 closed out, a net change of -12 holders.
- The largest Coherus Oncology buyer in Q3 2017 was Temasek Holdings, an estimated $86.7M added.
- The largest Coherus Oncology seller in Q3 2017 was PFM Health Sciences, an estimated $25.9M sold.
Based on aggregated 13F filings for Q3 2017.